Compare US Global Jets ETF (JETS) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs Revvity Inc — how do they compare? US Global Jets ETF trades at $31.64, while Revvity Inc trades at $115.97 (market cap $12.91B). The key difference: Revvity Inc pays a 0.24% dividend while US Global Jets ETF pays none, and Revvity Inc is trading nearer its 52-week high, US Global Jets ETF nearer its low. Which is the better fit depends on your goals.
| JETS | RVTY | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $33.53 | $117.75 |
52-Week Low | $23.64 | $82.26 |
Market Cap | — | $12.91B |
Enterprise Value | — | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JETS trades at $31.66, up 0.7% today, with a bullish technical signal from moving averages but neutral oscillators. Recent news highlights airline earnings beats and government rebates for retrofits, though fuel cost volatility remains a concern. The ETF focuses on U.S. airline operators, offering exposure to travel demand but facing cyclical risks.
Outlook is mixed: strong travel demand and lower oil prices support upside, but high fuel cost sensitivity and geopolitical tensions pose risks. Investors should weigh solid valuation metrics against sector volatility and macroeconomic headwinds for balanced exposure.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
